Collegium Pharmaceutical (NASDAQ:COLL) Shares Up 4.6% – Still a Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares shot up 4.6% during trading on Thursday . The company traded as high as $29.85 and last traded at $29.79. 186,192 shares traded hands during trading, a decline of 56% from the average session volume of 421,693 shares. The stock had previously closed at $28.47.

Analysts Set New Price Targets

A number of brokerages recently commented on COLL. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday, January 10th. Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a 50 day simple moving average of $30.78 and a 200-day simple moving average of $33.23. The stock has a market cap of $910.26 million, a P/E ratio of 12.46 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. On average, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 93,567 shares of company stock worth $2,774,710. Company insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in COLL. Robeco Institutional Asset Management B.V. raised its holdings in Collegium Pharmaceutical by 265.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 114,965 shares of the specialty pharmaceutical company’s stock worth $4,442,000 after purchasing an additional 83,548 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Easterly Investment Partners LLC grew its position in Collegium Pharmaceutical by 31.7% in the third quarter. Easterly Investment Partners LLC now owns 56,158 shares of the specialty pharmaceutical company’s stock worth $2,170,000 after acquiring an additional 13,529 shares in the last quarter. CWA Asset Management Group LLC purchased a new position in Collegium Pharmaceutical in the third quarter worth about $434,000. Finally, Meritage Portfolio Management purchased a new position in Collegium Pharmaceutical in the third quarter worth about $764,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.